Dr Susan Foden
Highly experienced biochemist Dr Susan Foden holds an MA and DPhil in Natural Sciences from the University of Oxford and brings more than 20 years of board experience to her role at QBiotics.
Dr Foden's background also includes pharmaceutical drug development and commercialisation, as well as extensive experience with the biotechnology investment community.
Dr Foden has served as a director on the boards of small and medium size private and public healthcare companies in the UK, Norway, Germany and Belgium, with recent board positions including BTG plc (acquired by Boston Scientific in 2019), and Vectura Group plc where she served for over 10 years as Senior Independent Director and Chair of the Remuneration Committee until 2019.
Dr Foden also chaired, and was a director of, BerGenBio ASA through its initial public offer on the Oslo Bohrs in 2015. Currently Dr Foden is a director of Evgen Pharma plc and Oxford Ancestors Ltd and is an Investment Committee member of CD3, the drug discovery initiative between the European Investment Fund and the University of Leuven in Belgium.